The availability of
G-CSF increases the safety margin of
chemotherapy use, especially in the management of
infection. This in turn makes administration of a more intense regimen of
chemotherapy possible. However, this improvement in neutropenic management could lead to an undesirable concurrent rise in
thrombocytopenia risk due to the higher dose of
chemotherapy administered. Although mortality from
thrombocytopenia is generally quite rare, transfusions of platelets are often expensive and can be associated with side effects such as
fever,
hypersensitivity reaction, and occasionally
infection. Therefore, transfusion of platelets should be performed when it is truly indicated. In general, the threshold for
platelet transfusion is accepted as being when the platelet count drops below 10,000/microliter, unless there is an obvious
bleeding lesion or other coagulation abnormality, such as
DIC being identified in the patients. On the other hand,
thrombotic microangiopathy (TMA) can also occur as a rare complication of the
malignancy itself or from the associated
cancer chemotherapy. The major features of TMA are
thrombocytopenia and marked increases of destroyed erythrocytes and LDH in peripheral blood. Despite a low incidence, its high mortality rate makes it important for all physicians caring for
cancer patients to be aware of it, especially in view of the ready availability of successful treatments (e.g.,
plasma exchanges). Early diagnosis of TMA in patients receiving
chemotherapy requires special attention because some characteristics of TMA are often masked by common side-effects of
chemotherapy such as bone marrow suppression. Since delay in initiation of
plasma exchange could result in higher mortality, urgent hematology consultation should be obtained if TMA is ever suspected.